A Phase 2/3 Study in Adult and Pediatric Participants With SCD

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

429

Participants

Timeline

Start Date

September 22, 2022

Primary Completion Date

December 30, 2030

Study Completion Date

December 30, 2032

Conditions
Sickle Cell Disease
Interventions
DRUG

Osivelotor

Tablets which contain drug substance

Trial Locations (24)

20010

Children's National Hospital, Washington D.C.

22031

Inova Schar Cancer Institute, Fairfax

27514

UNC Health, Chapel Hill

30315

Sonar Clinical Research, Atlanta

30350

Alpha Clinical Research Georgia, Dunwoody

33317

Edward Jenner Research Group Center LLC, Plantation

33407

Pediatric Hematology / Oncology a division of Kidz Medical services, West Palm Beach

39110

Mississippi Center for Advanced Medicine, Madison

40600

KEMRI/CRDR, Siaya, KEMRI Clinical Research Annex, Kisumu

60612

University of Illinois at Chicago Clinical Research Center, Chicago

64108

University Health, Kansas City

70112

University Medical Center New Orleans, New Orleans

70805

LSU Health Baton Rouge-North Clinic, Baton Rouge

77030

McGovern Medical School at UTHealth, Houston

700233

Aminu Kano Teaching Hospital, Kano

06511

Smilow Cancer Hospital, New Haven

40110-060

Hospital Universitario Professor Edgar Santos, Salvador

50070-460

Multihemo Servicos Medicos S/A, Recife

14051-140

Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto

15090-000

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, São José do Rio Preto

01232-010

Esho Empresa De Servicos Hospitalares S.A/ Hospital Samaritano Higienopolis, São Paulo

01321-001

Real e Benemerita Associacao Portuguesa de Sao Paulo, São Paulo

05403-000

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo

00200

Center for Research In Therapeutic Sciences (CREATES), Strathmore University Medical Centre, Nairobi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD | Biotech Hunter | Biotech Hunter